Dublin, Nov. 24, 2017 -- The "Generic Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report has been added to Research and Markets' offering.
The global generic injectables market reached a value of more than US$ 43 Billion in 2016, exhibiting a CAGR of around 9% during 2009-2016.
Owing to the advantages offered by generic injectables, governments in various countries are supporting their manufacture. Additionally, an increase in drug shortages, especially in the US, along with patent expiry of a number of blockbuster drugs, aging population and rising prevalence of chronic as well as lifestyle diseases represent some of the other factors driving the growth of the market. According to Generic Injectables Market:
The report has segmented the market on the basis of therapeutic area as oncology, anaesthesia, anti-infectives, parenteral nutrition, cardiovascular and others. Currently, the oncology segment accounts for the majority of the total market share. Further, the report has segmented the market on the basis of distribution channels covering hospitals and retail pharmacy stores. Among these, hospitals account for the largest market share. On a regional-basis, the report covers North America, Europe, Asia, Latin America, and Middle East and Africa. North America represents the largest region, accounting for more than a half of the total global share.
The report has also analysed the competitive landscape of the market with some of the key players being Hospira (Pfizer), Fresenius Kabi, Hikma, Sandoz (Novartis), Sagent, Sanofi and Baxter.
Key Topics Covered:
1 Preface
2 Scope and Methodology
2.1 Objectives of the study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Drug Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Breakup by Region
5.4 Market Forecast
5.5 Major Players
6 Global Generic Drug Delivery Market
6.1 Oral
6.2 Injectables
6.3 Dermal/Topical
6.4 Inhalers
7 Global Generic Injectables Market
7.1 Market Overview
7.2 Market Performance
7.3 Market Breakup by Region
7.4 Market Breakup by Therapeutic Area
7.5 Market Breakup by Distribution Channel
7.6 Market Forecast
7.7 SWOT Analysis
7.7.1 Strengths
7.7.2 Weaknesses
7.7.3 Opportunities
7.7.4 Threats
7.8 Value Chain Analysis
7.9 Porter's Five Forces Analysis
7.9.1 Overview
7.9.2 Bargaining Power of Buyers
7.9.3 Bargaining Power of Suppliers
7.9.4 Degree of Competition
7.9.5 Threat of New Entrants
7.9.6 Threat of Substitutes
7.10 Key Market Drivers and Success Factors
8 Global Generic Injectables Market: Performance of Key Regions
8.1 North America
8.2 Europe
8.3 Asia
8.4 Latin America
8.5 Middle East and Africa
9 Market by Therapeutic Area
9.1 Oncology
9.2 Anaesthesia
9.3 Anti-infectives
9.4 Parenteral Nutrition
9.5 Cardiovascular
10 Market by Distribution Channel
10.1 Hospitals
10.2 Retail Pharmacy Stores
11 Global Generic Injectable Market: Competitive Landscape
11.1 Competitive Structure
11.2 Market Breakup by Key Players
12 Generic Injectable Manufacturing Process
12.1 Product Overview
12.2 Detailed Process Flow (Injectable)
12.3 Various Types of Unit Operations Involved
12.4 Mass Balance and Raw Material Requirements
13 Project Details, Requirements and Costs Involved
13.1 Land Requirements and Expenditures
13.2 Construction Requirements and Expenditures
13.3 Plant Machinery
13.4 Machinery Pictures
13.5 Raw Material Requirements and Expenditures
13.6 Packaging Requirements and Expenditures
13.7 Transportation Requirements and Expenditures
13.8 Utility Requirements and Expenditures
13.9 Manpower Requirements and Expenditures
13.10 Other Capital Investments
14 Loans and Financial Assistance
15 Project Economics
15.1 Capital Cost of the Project
15.2 Techno-Economic Parameters
15.3 Product Pricing and Margins Across Various Levels of the Supply Chain
15.4 Taxation and Depreciation
15.5 Income Projections
15.6 Expenditure Projections
15.7 Financial Analysis
15.8 Profit Analysis
16 Key Player Profiles
For more information about this report visit https://www.researchandmarkets.com/research/r7nf8p/generic
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables


SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Instagram Outage Disrupts Thousands of U.S. Users
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



